ASCO GU 2024: CheckMate 914 Trial – Adjuvant Nivolumab Monotherapy vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy
This article reviews the outcomes of the CheckMate 914 trial, primarily focusing on Part B, which examined the efficacy of adjuvant Nivolumab (NIVO) monotherapy versus placebo (PBO) in patients with high-risk localized renal cell carcinoma (RCC) post-nephrectomy.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
